Scholars Central

Mini reviewPublished 29 Jul 2022

Immune enhancement therapy in COVID-19 patients: A mini review.

Authors: Wen Fei

Immunology Case Reports

Volume 5 · Issue 4 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

In March 2020, when COVID sickness 2019 (COVID-19) was simply starting to spread all over the planet, we introduced the expected advantages and contentions of calming treatment in COVID-19 patients in view of the restricted insight and proposed a few kinds of mitigating drugs with likely remedial worth, while without proof based information. In another year, numerous clinical preliminaries or certifiable examinations have been performed, either verify or refute the viability of specific mitigating drugs in the treatment of COVID-19. In this audit we sum up the advancement of mitigating and resistant treatment in COVID-19, including glucocorticoids, IL-6 bad guy, IL-1 inhibitor, kinase inhibitors, non-steroidal calming medications and chloroquine/ hydroxychloroquine.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalImmunology Case Reports
  • SubjectImmunology & Microbiology
  • BylineArticles whose byline prints “Wen Fei”